Piribedil
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Piribedil.svg | |
| Piribedil
| |
| Systematic (IUPAC) name | |
| 2-[4-(benzo[1,3]dioxol-5-ylmethyl)piperazin-1-yl]pyrimidine | |
| Identifiers | |
| CAS number | |
| ATC code | N04 |
| PubChem | |
| Chemical data | |
| Formula | C16H18N4O2 |
| Mol. mass | 298.340 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 1.7 – 6.9 hours |
| Excretion | Renal (68%) and biliary (25%) |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Piribedil is a piperazine dopamine agonist; and marketed as TRIVASTAL Retard 50.
Trivastal retard 50 is also distributed as: Trastal, Trivastal 50 retard, Trivastal 50mg LP, Trivastan ritardo and Pronoran.
Contents |
Composition:
Piribedil 50 mg per tablet - sustained-release.
Indications:
- Treatment of Parkinson's disease, either as monotherapy (without L-dopa) or in combination with L-dopa therapy, in the early stages as well as in the advanced stages. - Treatment of pathological cognitive deficits in the elderly (impaired attention, memory, etc). Treatment of dizziness in the elderly. - Treatment of Retinal ischemic manifestations. Adjuvant treatment in intermittent claudication due to peripheral occlusive arterial disease of the lower limbs (stage 2). - (off label) anhedonia and treatment-resistant depression in unipolar and bipolar depressives
Dosage:
In Parkinson's disease: administration of Trivastal retard 50 should be initiated with 1 tablet daily during the first week. Dosage should then be gradually increased every week until achieving the optimal therapeutic dose: as monotherapy: 3 to 5 tablets in 3 to 5 divided doses daily. In combination with L-dopa therapy: 1 to 3 tablets daily. In other indications: 1 tablet daily at the end of the main meal. In severe cases: 2 tablets daily as 2 divided doses.
Trivastal retard 50 is a nonergot dopamine agonist, selective for D2 and D3 dopamine receptors subtypes at the cerebral and at the peripheral level.
Cardiogenic shock. Acute phase of myocardial infarction.
Adverse:
rare side effects: minor gastrointestinal disorders (nausea, vomiting, flatulence) in predisposed individuals, or when taken between meals. They may resolve with the following: individual dosage adjustment, and/or addition of domperidone. Orthostatic hypotension or drowsiness may occur, particularly in predisposed individuals (underlying condition or causative illness).
Dopaminergic antagonists.
Overdosage:
At very high doses, Trivastal retard 50 has an emetic action on the CTZ (chemoreceptive trigger zone). Tablets will thus be rapidly rejected, which explains why no data are currently available concerning the risk of overdosage.
Anti-parkinson drugs: dopaminergic agents (N04B) | |
|---|---|
| Dopa and derivatives | Levodopa, Melevodopa, Etilevodopa |
| Adamantane derivatives | Amantadine |
| Dopamine agonists | Apomorphine, Bromocriptine, Cabergoline, Dihydrexidine, Dihydroergocryptine mesylate, Fenoldopam, Lisuride, Pergolide, Piribedil, Pramipexole, Quinpirole, Ropinirole, Rotigotine, SKF 38393, SKF 82958 |
| MAOIs | Selegiline, Rasagiline |
| Other | Tolcapone, Entacapone, Budipine |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
